Axxium
Preventing Alzheimer’s,
proprietary AI-powered biologics for chronic diseases*
Coming Soon
:>Tech
// h.a.l.
*Ideated since 2012 and implemented since 2014, we’ve been using h.a.l. as our personal biologic drug discovery partner. Because of that, in over 10 trials and half a dozen targets, we’ve had throughput that’s 2x faster and less than 1/10th of the cost, with over 5x chance of success.
:> Science
// Our Active Immunotherapy Medicine (AIM) platform
_Our AIM is a high-precision drug that trains the human body to make natural, personalized antibodies against chronic diseases.
_We leverage the wisdom of the immune system to treat and prevent diseases of population health.
_This is not hypothetical. We have been de-risking the AIM technology for 20 years.
// Proof of Concept, Proof of Mechanism, Proof of Technology achieved
_Approved :: Billions of AIM doses in animal health sold
_>10 :: Safe human clinical trials
_>4,200 :: Participants dosed
_>98% :: Patients generated antibodies
// Alzheimer’s Prevention
Our Alzheimer’s candidate is the only privately controlled Phase 3 globally accessible immunotherapy for prevention.
_According to Grok 3: Preventing Alzheimer’s on a global scale requires a strategy that’s effective, scalable, accessible, and cost-efficient, addressing the disease’s complexity across diverse populations. Based on current scientific understanding and practical considerations as of March 25, 2025, the most promising mechanism for global prevention centers on targeting toxic amyloid-beta oligomers through active immunotherapy, with AXX-AD emerging as the leading drug candidate for this ambitious goal.
// Publications
[Nature Medicine]
AIM: Parkinson’s
*Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial# 2024 <read me>
[Lancet BioMedicine]
AIM: Alzheimer's
*Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study# 2023 <read me>
[Nature Communications Medicine]
AIM: Migraine
*Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide# 2025 <read me>
[Journal of Lipid Research]
AIM: Hypercholesterolemia
*VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys# 2024 <read me>
[Acta Neuropathol]
AIM: Parkinson’s
*Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut# 2022 <read me>
[Movement Disorders]
AIM: Parkinson’s
*A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine# 2022 <read me>
[Alzheimer's Research & Therapy]
AIM: Parkinson’s
*Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy# 2020 <read me>
[Alzheimer's & Dementia]
AIM: Alzheimer's
*UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease# 2017 <read me>
[Vaccine]
AIM: Alzheimer's
*Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease# 2007 <read me>
:> Targets
1.Alzheimer’s (Aβ)
2.Parkinson’s + Dementia with Lewy Body(α-synuclein)
3.Food_allergy (IgE)
4.Migraine (CGRP)
5.Metabolic_disorders (Myostatin + Activin A)
:> Team
// Lou Reese, Executive Chairman
_Lou is a mission-driven entrepreneur dedicated to reducing unnecessary suffering through impact in healthcare, energy, real estate, and regenerative agriculture. In biotech, he has chaired or controlled companies that produce hundreds of millions of drug doses annually, immunize 25% of the world’s swine, and operate >2M sq ft of facilities. Through Axxium, he uses the proprietary AI platform h.a.l. to design drugs targeting Alzheimer’s, Parkinson’s, and chronic diseases; via Cana Life, he works to end HIV/AIDS deaths.
He pioneered early LEED multi-family projects, co-launched Hawaii’s leading solar integrator and one of the first global solar funds, and founded a closed-loop biodynamic/permaculture farm with major collections of banana, avocado, and taro varieties.
Lou spends months each year living off-grid with his family. Together with his wife and partner of 20+ years Mei Mei Hu they have been recognized as E&Y Entrepreneur of the Year finalists, Time 100 Next, Fortune 40 Under 40, World Economic Forum Young Global Leaders, and more. He holds a BA from the University of Pennsylvania, briefly worked in investment banking, and has three children.
// Mei Mei Hu, CEO
_Mei Mei led the launch of a pioneering active immunotherapy platform and the spin-out of five companies, including Vaxxinity’s NASDAQ IPO. She serves on the Strategic Initiatives Group for MAHA, and supports the First Lady’s Fostering the Future. A former consultant at McKinsey & Company and co-founder of an investment and advisory group with active investments in real estate, energy and life sciences, she’s recognized on Time 100 Next list, Fortune 40 under 40, and is a member of the Young Global Leaders of World Economic Forum. She holds a BA from University of Pennsylvania and her JD from Harvard Law School
// Rachelle Doody, CMO and Head of Development
_Rachelle, former global head of neurodegeneration and franchise head at Roche and Genentech, oversaw Alzheimer’s, Parkinson’s, Huntington’s disease, and ALS programs. She founded and directed Baylor College of Medicine’s Alzheimer’s Disease and Memory Disorders Center, and held the Effie Marie Cain Chair in AD Research. A prolific author with over 200 publications, she served on NIH-funded Alzheimer’s Disease Cooperative Study, Alzheimer’s Disease Neuroimaging Initiative, and Alzheimer’s Therapeutic Research Institute. She was elected to the Best Doctors in America list (1996-2016) and has received multiple awards, including the Distinguished Alumni Award from Rice University (2009), and Baylor’s Distinguished Faculty Award (2011).
// JC Dodart, Chief Scientific Officer
_JC has more than 20 years of neuroscience drug development experience from Lilly, Merck, Novartis, Sage Therapeutics and Wave Life Sciences. With expertise in Alzheimer’s, Parkinson’s, neuromuscular disorders, pain and depression, he holds an MS in cell biology and physiology from University Pierre & Marie Curie in Paris and a PhD in neuroscience from University Louis Pasteur, Strasbourg.
//
Synchronicity is here.
We are mission critical to the new system.
Axxium
© 2025